Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

BACKGROUND: Abiraterone acetate (abiraterone) prolongs overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC). This study's objective was to retrospectively identify factors associated with prostate-specific antigen (PSA) response to abiraterone and valid...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Oncol
Asıl Yazarlar: Leibowitz-Amit, R., Templeton, A. J., Omlin, A., Pezaro, C., Atenafu, E. G., Keizman, D., Vera-Badillo, F., Seah, J.-A., Attard, G., Knox, J. J., Sridhar, S. S., Tannock, I. F., de Bono, J. S., Joshua, A. M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2014
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4433513/
https://ncbi.nlm.nih.gov/pubmed/24458472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt581
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller